JP2023548581A5 - - Google Patents

Info

Publication number
JP2023548581A5
JP2023548581A5 JP2023527227A JP2023527227A JP2023548581A5 JP 2023548581 A5 JP2023548581 A5 JP 2023548581A5 JP 2023527227 A JP2023527227 A JP 2023527227A JP 2023527227 A JP2023527227 A JP 2023527227A JP 2023548581 A5 JP2023548581 A5 JP 2023548581A5
Authority
JP
Japan
Prior art keywords
polypeptide
bacteriophage
virus
crispr
cas system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058123 external-priority patent/WO2022098916A1/en
Publication of JP2023548581A publication Critical patent/JP2023548581A/ja
Publication of JP2023548581A5 publication Critical patent/JP2023548581A5/ja
Pending legal-status Critical Current

Links

JP2023527227A 2020-11-05 2021-11-04 Ｃｒｉｓｐｒ－ｃａｓ系を含むシュードモナスに対するファージ組成物およびその使用方法 Pending JP2023548581A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063110288P 2020-11-05 2020-11-05
US63/110,288 2020-11-05
US202163184728P 2021-05-05 2021-05-05
US63/184,728 2021-05-05
PCT/US2021/058123 WO2022098916A1 (en) 2020-11-05 2021-11-04 Phage compositions for pseudomonas comprising crispr-cas systems and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023548581A JP2023548581A (ja) 2023-11-17
JP2023548581A5 true JP2023548581A5 (enExample) 2024-11-13

Family

ID=81458404

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527227A Pending JP2023548581A (ja) 2020-11-05 2021-11-04 Ｃｒｉｓｐｒ－ｃａｓ系を含むシュードモナスに対するファージ組成物およびその使用方法

Country Status (8)

Country Link
US (1) US20240011041A1 (enExample)
EP (1) EP4240165A4 (enExample)
JP (1) JP2023548581A (enExample)
AU (1) AU2021373795A1 (enExample)
CA (1) CA3197191A1 (enExample)
TW (1) TW202233832A (enExample)
UY (1) UY39506A (enExample)
WO (1) WO2022098916A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960895B (zh) * 2022-08-09 2026-04-10 中国科学院微生物研究所 一种偶联的crispr和毒素-抗毒素元件及其在消杀耐药细菌中的应用
EP4712993A2 (en) * 2023-05-17 2026-03-25 The Regents of the University of California Phage therapy for alcohol-associated hepatitis
WO2025076308A1 (en) * 2023-10-06 2025-04-10 University Of Florida Research Foundation, Incorporated Compositions and methods for analyzing the effect of microbiota on host protein conformation and treating neurodegenerative diseases
CN117959655B (zh) * 2024-01-31 2026-06-23 四川大学 一种假单胞菌还原剂及其在钒还原中的应用和方法
WO2025206239A1 (ja) * 2024-03-28 2025-10-02 国立感染症研究所長が代表する日本国 組換えファージ及び遺伝子のスクリーニング方法
WO2026150377A1 (en) 2025-01-13 2026-07-16 Locus Biosciences, Inc. Bacteriophage compositions and uses for treatment of escherichia coli (e. coli) colonization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107208070B (zh) * 2014-11-26 2021-09-07 技术创新动力基金（以色列）有限合伙公司 细菌基因的靶向消除
AU2016280002B2 (en) * 2015-06-15 2022-04-14 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
GB201710126D0 (en) * 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
US20230193241A1 (en) * 2017-06-25 2023-06-22 Snipr Technologies Limited Altering microbial populations & modifying microbiota
US20190160120A1 (en) * 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
KR20210018273A (ko) * 2018-05-04 2021-02-17 로커스 바이오사이언스, 인크. 표적 박테리아를 사멸시키기 위한 방법 및 조성물
WO2019227080A1 (en) * 2018-05-25 2019-11-28 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
US20220370526A1 (en) * 2019-11-06 2022-11-24 Locus Biosciences, Inc. Phage compositions comprising crispr-cas systems and methods of use thereof

Similar Documents

Publication Publication Date Title
US11491209B2 (en) Sequence specific antimicrobials
JP6849435B2 (ja) 治療薬
JP6860483B2 (ja) 細菌遺伝子の標的化削減
US20210322525A9 (en) Sequence specific antimicrobials
US20230248789A1 (en) Therapeutic bacteriophage compositions for treating staphylococcus infection
JP7449967B2 (ja) 療法バクテリオファージ組成物
US10106784B2 (en) Modified bacteriophage
JP7141756B2 (ja) 異なる尾繊維を有する複数宿主域のバクテリオファージ
Dhungana et al. Therapeutic efficacy of bacteriophage therapy to treat carbapenem resistant Klebsiella pneumoniae in mouse model
Li et al. A novel Saclayvirus Acinetobacter baumannii phage genomic analysis and effectiveness in preventing pneumonia
JP2021525105A5 (enExample)
JP2021508501A (ja) Ｐｓｅｕｄｏｍｏｎａｓ感染症を処置するためのバクテリオファージ組成物
Ceballos-Garzon et al. Phages, anti-CRISPR proteins, and drug-resistant bacteria: what do we know about this triad?
US20040156831A1 (en) Bacteriophage having modified holin and uses thereof
US11732243B2 (en) Anti-bacterial compositions comparing lytic modified bacteriophage engineered to infect and kill different target bacteria
US20170333500A1 (en) Genetically Modified Bacteriophage (Bio-Phage)
JP2023548580A5 (enExample)
Aishat et al. An overview on the application of bacteriophage therapy in combating antibiotics resistance: A review
Lu et al. Engineering synthetic bacteriophage to combat antibiotic-resistant bacteria
Roman et al. Pf Bacteriophage and Their Impact on Pseudomonas Virulence, Mammalian Immunity, and Chronic
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection
Pashu et al. IAVMI-2014
Godány et al. Phage therapy: Alternative approach to antibiotics
Bell et al. Better Luck Next Time: The Tesurrection of Bacteriophage Therapy